Corline Biomedical AB Total Assets
Corline Biomedical AB total assets. Based on the latest financial reports, Corline Biomedical AB (CLBIO) holds total assets worth Skr114.18 Million SEK (≈ $12.29 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CLBIO market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Corline Biomedical AB (2012–2025)
Total assets of Corline Biomedical AB from 2012 to 2025. This chart illustrates how Corline Biomedical AB's total assets have evolved over time, based on quarterly financial data. See Corline Biomedical AB stock price for real-time trading data and today's change.
Corline Biomedical AB - Asset Composition Analysis
Corline Biomedical AB Total Assets Breakdown (December 2025)
Corline Biomedical AB total assets breakdown as of December 2025. Corline Biomedical AB's total assets of Skr114.18 Million consist of 24.3% current assets and 75.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr20.56 Million | 20.9% |
| Accounts Receivable | Skr2.31 Million | 2.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr162.00K | 0.2% |
| Intangible Assets | Skr74.43 Million | 75.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Corline Biomedical AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Corline Biomedical AB (CLBIO) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Corline Biomedical AB's current assets represent 24.3% of total assets in 2025, a decrease from 28.8% in 2012.
- Cash Position: Cash and equivalents constituted 20.9% of total assets in 2025, up from 18.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 75.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 75.5% of total assets.
Corline Biomedical AB Competitors by Total Assets
Key competitors of Corline Biomedical AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Corline Biomedical AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.48 | 2.09 | 11.85 |
| Quick Ratio | 6.26 | 2.09 | 11.85 |
| Cash Ratio | 0.00 | 1.44 | 11.40 |
| Working Capital | Skr33.20 Million | Skr6.30 Million | Skr40.89 Million |
Corline Biomedical AB - Advanced Valuation Insights
This section examines the relationship between Corline Biomedical AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.18 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | Skr98.58 Million |
| Market Capitalization | $37.69 Million USD |
Valuation Analysis
Below Book Valuation: The market values Corline Biomedical AB's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Corline Biomedical AB's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Corline Biomedical AB (2012–2025)
The table below shows the annual total assets of Corline Biomedical AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr98.58 Million ≈ $10.61 Million |
+4.03% |
| 2024-12-31 | Skr94.76 Million ≈ $10.20 Million |
-5.34% |
| 2023-12-31 | Skr100.11 Million ≈ $10.77 Million |
-1.65% |
| 2022-12-31 | Skr101.78 Million ≈ $10.95 Million |
+0.12% |
| 2021-12-31 | Skr101.66 Million ≈ $10.94 Million |
+74.43% |
| 2020-12-31 | Skr58.28 Million ≈ $6.27 Million |
-8.58% |
| 2019-12-31 | Skr63.75 Million ≈ $6.86 Million |
+1.33% |
| 2018-12-31 | Skr62.91 Million ≈ $6.77 Million |
+22.34% |
| 2017-12-31 | Skr51.43 Million ≈ $5.53 Million |
+24.60% |
| 2016-12-31 | Skr41.27 Million ≈ $4.44 Million |
+65.13% |
| 2015-12-31 | Skr24.99 Million ≈ $2.69 Million |
+49.02% |
| 2014-12-31 | Skr16.77 Million ≈ $1.81 Million |
+21.92% |
| 2013-12-31 | Skr13.76 Million ≈ $1.48 Million |
+10.41% |
| 2012-12-31 | Skr12.46 Million ≈ $1.34 Million |
-- |
About Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent ha… Read more